



Fig S1. Anti-VEGF therapies reduce no. of CD31-positive vessels in schwannoma. Vandetanib reduced no. of CD31-positive vessels in *Nf2-/-* by 62% (A). Both bevacizumab and vandetanib also produced similar anti-angiogenic outcome, where a 50% decrease of CD31-positive vessels was observed (B). All n=4; * $p=0.013$, ** $p=0.0055$ and *** $p=0.046$.